3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
50
Gynecologic
3
Thoracic
1
Sarcoma
1
Plasma cell
1
Genitourinary
1
Dermatologic
1
Conditions
Sarcoma
142
Osteosarcoma
26
Liposarcoma
25
Leiomyosarcoma
25
Histiocytoma, Malignant Fibrous
19
Hemangiosarcoma
18
Sarcoma, Synovial
17
Neurofibrosarcoma
17
Fibrosarcoma
17
Rhabdomyosarcoma
16
Dendritic Cell Sarcoma, Interdigitating
16
Sarcoma, Ewing
13
Neuroectodermal Tumors, Primitive, Peripheral
11
HIV Infections
11
Sarcoma, Kaposi
10
Neoplasms
10
Neoplasm Metastasis
10
Malignant mesenchymal tumor
10
Acquired Immunodeficiency Syndrome
10
Lymphoma, Large B-Cell, Diffuse
9
Dermatofibrosarcoma
9
Ovarian Neoplasms
8
Lymphoma
8
Hemangiopericytoma, Malignant
8
Desmoplastic Small Round Cell Tumor
8
Sarcoma, Alveolar Soft Part
6
Chondrosarcoma, Extraskeletal Myxoid
6
Bone Neoplasms
6
Chondrosarcoma
5
Burkitt Lymphoma
5
Interventions
pembrolizumab
7
Cyclophosphamide
6
Nivolumab
4
fludarabine
3
spartalizumab
2
aldesleukin
2
Trastuzumab
2
Standard of Care
2
Specimen Handling
2
Magnetic Resonance Spectroscopy
2
Irinotecan
2
Ipilimumab
2
Gemcitabine
2
zanidatamab
1
vocimagene amiretrorepvec
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
toripalimab
1
tislelizumab
1
tinostamustine
1
talazoparib
1
sarilumab
1
sargramostim
1
regorafenib
1
pexidartinib
1
pertuzumab
1
pegfilgrastim
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Triple Negative Breast Neoplasms
×
Doxorubicin
×
Sarcoma
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled